ICU · Respiratory
Massive haemoptysis in ICU
Also known as Massive haemoptysis · Life-threatening haemoptysis · Pulmonary haemorrhage · Bronchial artery embolisation
Massive haemoptysis: commonly defined as a blood loss of 600 mL/24 h or at a rate that poses a threat to life; trials operationalise massive as over 200 mL/24 h with haemodynamic or respiratory instability, and any amount causing airway compromise counts. True emergency — death from ASPHYXIATION (not exsanguination), sometimes within minutes. Causes: unknown in about half of cases; infectious/inflammatory airway diseases (incl. bronchiectasis) 25.8%, cancer 17.4%, TB (active and old cavities with mycetoma), pneumonia, vasculitis, AVM, trauma, iatrogenic. About 90% of bleeding arises from the BRONCHIAL (systemic) circulation. Management: (1) Protect airway — position bleeding side DOWN. (2) Oxygenate; intubate if necessary (large single-lumen ETT, double-lumen tube or blocker for lung isolation). (3) Bronchoscopy (rigid preferred for brisk bleeding; wedging, cold saline lavage, regional vasoconstrictors, balloon tamponade). (4) Bronchial artery embolisation (BAE) — first-line definitive, successful haemostasis in 75-98%; recurrence 13.9% at 12 months. (5) Surgery when BAE fails or for special indications (traumatic or iatrogenic pulmonary/vascular injury, refractory aspergilloma).
Checked against its sources on 14 Oct 2026
Practise this topic
On this page
Study tools
Your progress
Saved on this device.
Target exams
Red flags
- Death from ASPHYXIATION (not exsanguination) — airway protection is the priority
- Position bleeding side DOWN — prevent blood flooding contralateral lung
- Bronchial artery embolisation (BAE) — first-line definitive treatment; successful haemostasis in 75-98% of cases
- Aspergilloma (mycetoma) — classic cause of massive haemoptysis in TB cavities
- 90% of bleeding from BRONCHIAL arteries (systemic, high-pressure) — explains brisk haemorrhage
Definition
| Category | Volume | Clinical implication |
|---|---|---|
| Persistent minor | under 200 mL / 24 h | Investigate; surgery within 4 days if persistent (TB surgical series) |
| Major | 200-600 mL / 24 h | Admit; urgent control — surgery within 2 days in the TB series |
| Massive (surgical series) | over 600 mL / 24 h | Emergency — ICU, airway protection, definitive therapy; urgent surgery |
| Massive (trial operational threshold) | over 200 mL / 24 h | Exclusion criterion for 'massive' in the inhaled-tranexamic-acid randomised trial |
| Exsanguinating | over 1000 mL at a rate of at least 150 mL/h | Life threatened by blood loss itself — the resection-series subgroup |
There is no single universally agreed volume threshold for "massive" haemoptysis. Published definitions include a blood loss of 600 mL in 24 hours or at a rate that poses a threat to life[11], surgical series that band severity as minor under 200 mL/day, major 200-600 mL/day, and massive over 600 mL/day[16], and randomised trials that operationalise massive as over 200 mL/24 h with haemodynamic or respiratory instability[13]. Volume is an imperfect marker because death may occur within minutes from asphyxiation — the primary prognostic factors are the rate of bleeding and the underlying cardiopulmonary status of the patient — so the threat to gas exchange, not the measured millilitres, dictates urgency.[17] A practical ICU rule — any haemoptysis that contaminates the contralateral lung or impairs ventilation is massive, regardless of mL.[5]
References26ShowHide
- [1]Ittrich H, Bockhorn M, Klose H, Simon M, et al. The Diagnosis and Treatment of Hemoptysis Dtsch Arztebl Int, 2017.PMID 28625277
- [2]Sakr L, Dutau H. Massive hemoptysis: an update on the role of bronchoscopy in diagnosis and management Respiration, 2010.PMID 20090288
- [3]Kettenbach J, Ittrich H, Gaubert JY, et al. CIRSE Standards of Practice on Bronchial Artery Embolisation Cardiovasc Intervent Radiol, 2022.PMID 35396612
- [4]Valipour A, Kreuzer A, Koller H, Koessler W, Burghuber OC. Bronchoscopy-guided topical hemostatic tamponade therapy for the management of life-threatening hemoptysis Chest, 2005.PMID 15947328
- [5]Jean-Baptiste E. Clinical assessment and management of massive hemoptysis Crit Care Med, 2000.PMID 10834728
- [6]Larici AR, Franchi P, Occhipinti M, et al. Diagnosis and management of hemoptysis Diagn Interv Radiol, 2014.PMID 24808437
- [7]Ittrich H, Klose H, Adam G. Radiologic management of haemoptysis: diagnostic and interventional bronchial arterial embolisation Rofo, 2015.PMID 25372159
- [8]Campos JH, Musselman ED, Hanada S, et al. Lung Isolation Techniques in Patients With Early-Stage or Long-Term Tracheostomy: A Case Series Report of 70 Cases and Recommendations J Cardiothorac Vasc Anesth, 2019.PMID 30190202
- [9]Collins SR, Titus BJ, Campos JH, et al. Lung Isolation in the Patient With a Difficult Airway Anesth Analg, 2018.PMID 29189274
- [10]Ye M, Chen M, Wang C, et al. Nebulized Tranexamic Acid in the Management of Hemoptysis: An Integrative Review Lung, 2025.PMID 39841268
- [11]Noseworthy TW, Anderson BJ. Massive hemoptysis CMAJ, 1986.PMID 3533242
- [12]Yoon W, Kim JK, Kim YH, Chung TW, Kang HK. Bronchial and nonbronchial systemic artery embolization for life-threatening hemoptysis: a comprehensive review Radiographics, 2002.PMID 12432111
- [13]Wand O, Guber E, Guber A, Epstein Shochet G, Israeli-Shani L, Shitrit D. Inhaled Tranexamic Acid for Hemoptysis Treatment: A Randomized Controlled Trial Chest, 2018.PMID 30321510
- [14]Gopinath B, Mishra PR, Aggarwal P, et al. Nebulized vs IV Tranexamic Acid for Hemoptysis: A Pilot Randomized Controlled Trial Chest, 2023.PMID 36410494
- [15]Garzon AA, Cerruti MM, Golding ME. Exsanguinating hemoptysis J Thorac Cardiovasc Surg, 1982.PMID 7144217
- [16]Erdogan A, Yegin A, Gürses G, et al. Surgical management of tuberculosis-related hemoptysis Ann Thorac Surg, 2005.PMID 15620962
- [17]Karmy-Jones R, Cuschieri J, Vallières E Role of bronchoscopy in massive hemoptysis Chest Surg Clin N Am, 2001.PMID 11780301
- [18]Sadidi S, Roozafzai F, Nekooei S, Jarahi L, Khoroushi F. Predictors of 12-Month Recurrence of Hemoptysis after Bronchial Artery Embolization Arch Iran Med, 2025.PMID 40062498
- [19]Cordovilla R, Bollo de Miguel E, Nuñez Ares A, et al. Diagnosis and Treatment of Hemoptysis Arch Bronconeumol, 2016.PMID 26873518
- [20]Lee RW, D'Cruz DP. Novel therapies for anti-neutrophil cytoplasmic antibody-associated vasculitis Drugs, 2008.PMID 18416584
- [21]Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis N Engl J Med, 2010.PMID 20647199
- [22]McAdoo SP, Tanna A, Hrušková Z, et al. Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients Kidney Int, 2017.PMID 28506760
- [23]Moussi-Frances J, Sallée M, Jourde-Chiche N Apheresis to treat systemic vasculitis Joint Bone Spine, 2018.PMID 28602810
- [24]Casal A, Díaz-Garel J, Pereiro T, et al. Pulmonary vasculitis J Thorac Dis, 2018.PMID 30416807
- [25]Tayal M, Chauhan U, Sharma P, Dev R, Dua R, Kumar S. Bronchial artery embolization. What further we can offer? Wideochir Inne Tech Maloinwazyjne, 2020.PMID 32904618
- [26]O'Gurek D, Choi HYJ. Hemoptysis: Evaluation and Management Am Fam Physician, 2022.PMID 35166503